

Carla Minoia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5127572/publications.pdf>

Version: 2024-02-01

51
papers

854
citations

623734

14
h-index

552781

26
g-index

54
all docs

54
docs citations

54
times ranked

1673
citing authors

#	ARTICLE	IF	CITATIONS
1	Fertility preservation strategies for patients with lymphoma: a real-world practice survey among Fondazione Italiana Linfomi centers. <i>Tumori</i> , 2022, 108, 572-577.	1.1	10
2	Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 519.	3.7	2
3	Echocardiography Monitoring during Anthracycline Administration in Hodgkin and Non-Hodgkinâ€™s Lymphoma: The Tei Index Evaluation. <i>Journal of Personalized Medicine</i> , 2022, 12, 290.	2.5	2
4	Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 1439.	3.7	6
5	Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 61.	3.7	5
6	Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi. <i>Tumori</i> , 2021, 107, 91-94.	1.1	11
7	18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 123.	2.5	3
8	Body Composition Change, Unhealthy Lifestyles and Steroid Treatment as Predictor of Metabolic Risk in Non-Hodgkinâ€™s Lymphoma Survivors. <i>Journal of Personalized Medicine</i> , 2021, 11, 215.	2.5	5
9	Male and Female Fertility: Prevention and Monitoring Hodgkinâ€™ Lymphoma and Diffuse Large B-Cell Lymphoma Adult Survivors. A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2021, 13, 2881.	3.7	13
10	The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2021, 13, 3135.	3.7	9
11	Long-Term Follow-Up of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: Aims and Methodological Approach for Fondazione Italiana Linfomi Systematic Reviews. <i>Cancers</i> , 2021, 13, 2976.	3.7	5
12	Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2021, 13, 3401.	3.7	9
13	Primary, Bilateral and Diffuse Renal Non-Hodgkinâ€™s Lymphoma in a Young Woman Suffering from Turner Syndrome. <i>Journal of Personalized Medicine</i> , 2021, 11, 644.	2.5	2
14	Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 45.	1.5	20
15	Psychological Distress in Outpatients With Lymphoma During the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020, 10, 1270.	2.8	93
16	Novel aspects on gonadotoxicity and fertility preservation in lymphoproliferative neoplasms. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102981.	4.4	17
17	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective realâ€™world study. <i>European Journal of Haematology</i> , 2020, 104, 581-587.	2.2	10
18	Fertility Preservation in Cancer Patients During the Coronavirus (COVID-19) Pandemic. <i>Frontiers in Oncology</i> , 2020, 10, 1009.	2.8	16

#	ARTICLE	IF	CITATIONS
19	The Role of Circulating Adiponectin and SNP276G>T at <i>ADIPOQ</i> Gene in <i>BRCA</i>-mutant Women. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 301-307.	2.0	7
20	Long-Lasting Remission in De Novo Breast Myeloid Sarcoma Treated with Decitabine and Radiotherapy. <i>Diagnostics</i> , 2019, 9, 84.	2.6	9
21	Effects of Physical Exercise Intervention on Psychological and Physical Fitness in Lymphoma Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 379.	2.0	21
22	1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia. <i>Clinical and Experimental Medicine</i> , 2019, 19, 261-267.	3.6	4
23	Novel acquisitions on biology and management of transformed follicular lymphoma. <i>Hematological Oncology</i> , 2018, 36, 617-623.	1.7	3
24	Improvable Lifestyle Factors in Lymphoma Survivors. <i>Acta Haematologica</i> , 2018, 139, 235-237.	1.4	7
25	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , 2018, 5, e359-e367.	4.6	74
26	Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography. <i>Annals of Hematology</i> , 2017, 96, 1147-1153.	1.8	15
27	THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA "œTRANSFORMED" BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. <i>Hematological Oncology</i> , 2017, 35, 115-116.	1.7	8
28	Improving Provision of Care for Long-term Survivors of Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e1-e9.	0.4	17
29	u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. <i>BMC Cancer</i> , 2017, 17, 215.	2.6	20
30	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017, 58, 552-559.	1.3	9
31	Risk of lymphoma subtypes by occupational exposure in Southern Italy. <i>Journal of Occupational Medicine and Toxicology</i> , 2017, 12, 31.	2.2	13
32	Improvements in haematology for home health assistance and monitoring by a web based communication system. , 2016, , .		7
33	Autologous and allogeneic stem cell transplant in Jehovah's Witnesses: a single-center experience on 22 patients. <i>Bone Marrow Transplantation</i> , 2016, 51, 1002-1003.	2.4	5
34	The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "œreal life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2016, 95, 239-244.	1.8	46
35	Role of WB-MR/DWIBS compared to 18F-FDG PET/CT in the therapy response assessment of lymphoma. <i>Radiologia Medica</i> , 2016, 121, 132-143.	7.7	28
36	A supervised CAD to support telemedicine in hematology. , 2015, , .		12

#	ARTICLE	IF	CITATIONS
37	Real world outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the Rete Ematologica Pugliese. Leukemia Research, 2015, 39, 279-283.	0.8	11
38	Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis. Bone Marrow Transplantation, 2015, 50, 1486-1486.	2.4	1
39	Azacitidine in the front-line treatment of therapy-related myeloid neoplasms: a multicenter case series. Anticancer Research, 2015, 35, 461-6.	1.1	6
40	Challenges and Opportunities of MicroRNAs in Lymphomas. Molecules, 2014, 19, 14723-14781.	3.8	26
41	HIF-1 α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target. Clinical Cancer Research, 2014, 20, 847-858.	7.0	54
42	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leukemia Research, 2014, 38, 1446-1450.	0.8	13
43	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer, 2014, 14, 396.	2.6	10
44	Targeted Strategies in the Treatment of Primary Gastric Lymphomas: From Rituximab to Recent Insights into Potential New Drugs. Current Medicinal Chemistry, 2014, 21, 1005-1016.	2.4	4
45	Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma. Hellenic Journal of Nuclear Medicine, 2014, 17 Suppl 1, 40-9.	0.3	14
46	Changes in angiogenesis and hypoxia-inducible factor-1 α protein expression in relapsed/refractory indolent non-Hodgkin lymphomas. British Journal of Haematology, 2013, 163, 640-645.	2.5	11
47	Complete Response to Second Line Paclitaxel Every 2 Weeks of Eyelid Kaposi Sarcoma. Ophthalmic Plastic and Reconstructive Surgery, 2013, 29, e114-e115.	0.8	2
48	Antineoplastic drug-induced bradyarrhythmias. Expert Opinion on Drug Safety, 2012, 11, 739-751.	2.4	10
49	mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma. Current Medicinal Chemistry, 2012, 19, 945-954.	2.4	11
50	Staging multiple myeloma patients with active disease using serum levels of 226 Rn-free HLA class I heavy chain together with IgM or platelet count. Blood Cells, Molecules, and Diseases, 2009, 42, 71-76.	1.4	8
51	Rheumatic disorders as paraneoplastic syndromes. Autoimmunity Reviews, 2008, 7, 352-358.	5.8	129